Sensitive HPLC-Fluorescence Method for Irinotecan and Four Major Metabolites in Human Plasma and Saliva: Application to Pharmacokinetic Studies

Clinical Chemistry

Volumn 49, Issue 11, 2003, Pages 1900-1908

  Poujol, Sylvain ^a   Pinguet, Frédéric ^a   Malosse, Françoise ^a   Astre, Cécile ^a   Ychou, Marc ^b   Culine, Stéphane ^b   Bressolle, Françoise ^c  

^a Oncopharmacology Department   (France)

^b CENTRE VAL D AURELLE   (France)

^c UNIV MONTPELLIER   (France)

Author keywords

[No Author keywords available]

Indexed keywords

7 ETHYL 10 (4 AMINO 1 PIPERIDINO)CARBONYLOXYCAMPTOTHECIN; 7 ETHYL 10 [4 N (5 AMINOPENTANOIC ACID) 1 PIPERIDINO]CARBONYLOXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN; 7 ETHYL 10 HYDROXYCAMPTOTHECIN GLUCURONIDE; ANTIMITOTIC AGENT; CARBOXYLIC ACID; DRUG METABOLITE; HYDROCHLORIC ACID; IRINOTECAN; LACTONE; UNCLASSIFIED DRUG;

ACIDIFICATION; AREA UNDER THE CURVE; ARTICLE; COLORECTAL CANCER; CONTROLLED STUDY; DRUG ELIMINATION; DRUG HALF LIFE; DRUG STRUCTURE; FLUORESCENCE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HUMAN TISSUE; METASTASIS; NORMAL HUMAN; PRECIPITATION; SALIVA ANALYSIS;

ANTINEOPLASTIC AGENTS, PHYTOGENIC; CAMPTOTHECIN; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; COLORECTAL NEOPLASMS; DRUG STABILITY; GLUCURONATES; HUMANS; NEOPLASM METASTASIS; REPRODUCIBILITY OF RESULTS; SALIVA; SENSITIVITY AND SPECIFICITY; SPECTROMETRY, FLUORESCENCE;

EID: 0242362622     PISSN: 00099147     EISSN: None     Source Type: Journal    
DOI: 10.1373/clinchem.2003.023481     Document Type: Article

References (44)

1. Kunimoto T, Nitta K, Tanaka T, Uehara N, Baba H, Takeuchi M, et al. Antitumor activity of 7-ethyl-10-[4-(1-piperidino)-1-piperidino] carbonyloxy-camptothecin, a novel water-soluble derivative of camptothecin, against murine tumors. Cancer Res 1987;47:5944-7.
2. Sawada S, Okajima S, Aiyama R, Nokata K, Furuta T, Yokokura T, et al. Synthesis and antitumor activity of 20(S)-camptothecin derivatives: carbamate-linked, water-soluble derivatives of 7-ethyl-10-hydroxycamptothecin. Chem Pharm Bull 1991;39:1446-50.
3. Bissery MC, Mathieu-Boué A, Lavelle F. Preclinical evaluation of CPT-11, a camptothecin derivative. Proc Am Assoc Cancer Res 1991;32:402.
4. Tsuruo T, Matsuzaki T, Matsushita M, Saito H, Yokokura T. Antitumor effect of CPT-11, a new derivative of camptothecin, against pleiotropic drug-resistant tumors in vitro and in vivo. Cancer Chemother Pharmacol 1988;21:71-4.
5. Shimada Y, Yoshino M, Wakui A, Nakao I, Futatsuki K, Sakata Y, et al. Phase II study of CPT-11, a new camptothecin derivative, in metastatic colorectal cancer. CPT-11 Gastrointestinal Cancer Study Group. J Clin Oncol 1993;11:909-13.
6. Rothenberg ML, Eckardt JR, Kuhn JG, Burris HA 3rd, Nelson J, Hilsenbeck SG, et al. Phase II trial of irinotecan in patients with progressive or rapidly recurrent colorectal cancer. J Clin Oncol 1996;14:1128-35.
7. Conti JA, Kemeny NE, Saltz LB, Huang Y, Tong WP, Chou TC, et al. Irinotecan is an active agent in untreated patients with metastatic colorectal cancer. J Clin Oncol 1996;14:709-15.
8. Fukuoka M, Niitani H, Suzuki A, Motomiya M, Hasegawa K, Nishiwaki Y, et al. A phase II study of CPT-11, a new derivative of camptothecin, for previously untreated non-small-cell lung cancer. J Clin Oncol 1992;10:16-20.
9. Masuda N, Fukuoka M, Kusunoki Y, Matsui K, Takifuji N, Kudoh S, et al. CPT-11: a new derivative of camptothecin for the treatment of refractory or relapsed small-cell lung cancer. J Clin Oncol 1992;10:1225-9.
10. Creemers GJ, Lund B, Verweij J. Topoisomerase I inhibitors: topotecan and irinotecan. Cancer Treat Rev 1994;20:73-96.
11. Gerrits CJ, de Jonge MJ, Schellens JH, Stoter G, Verweij J. Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development. Br J Cancer 1997;76:952-62.
12. Hsiang YH, Hertzberg R, Hecht S, Liu LF. Camptothecin induces protein-linked DNA breaks via mammalian DNA topoisomerase I. J Biol Chem 1985;260:14873-8.
13. Hsiang YH, Liu LF. Identification of mammalian DNA topoisomerase I as an intracellular target of the anticancer drug camptothecin. Cancer Res 1988;48:1722-6.
14. Kessel D, Bosmann HB, Lohr K. Camptothecin effects on DNA synthesis in murine leukemia cells. Biochem Biophys Acta 1972;269:210-6.
15. Wang JC. DNA topoisomerase. Ann Rev Biochem 1985;54:665-97.
16. Hsiang YH, Liu LF, Wall ME, Wani MC, Nicholas AW, Manikumar G, et al. DNA topoisomerase I-mediated DNA cleavage and cytotoxicity of camptothecin analogues. Cancer Res 1989;49:4385-9.
17. Liu LF. DNA topoisomerase poisons as antitumor drugs. Annu Rev Biochem 1989;58:351-75.
18. Mathijssen RH, van Alphen RJ, Verweij J, Loos WJ, Nooter K, Stoter G, et al. Clinical pharmacokinetics and metabolism of irinotecan (CPT-11). Clin Cancer Res 2001;7:2182-94.
19. Kawato Y, Aonuma M, Hirota Y, Kuga H, Sato K. Intracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11. Cancer Res 1991;51:4187-91.
20. Canal P, Gay C, Dezeuze A, Douillard JY, Bugat R, Brunet R, et al. Pharmacokinetics and pharmacodynamics of irinotecan during a phase II clinical trial in colorectal cancer. Pharmacology and Molecular Mechanisms Group of the European Organization for Research and Treatment of Cancer. J Clin Oncol 1996;14:2688-95.
21. Rivory LP, Robert J. Identification and kinetics of a β-glucuronide metabolite of SN-38 in human plasma after administration of the camptothecin derivative irinotecan. Cancer Chemother Pharmacol 1995;36:176-9.
22. Haaz MC, Rivory L, Jantet S, Ratanasavanh D, Robert J. Glucuronidation of SN-38, the active metabolite of irinotecan, by human hepatic microsomes. Pharmacol Toxicol 1997;80:91-6.
23. Rivory LP, Riou JF, Haaz MC, Sable S, Vuilhorgne M, Commercon A, et al. Identification and properties of a major plasma metabolite of irinotecan (CPT-11) isolated from the plasma of patients. Cancer Res 1996;56:3689-94.
24. Dodds HM, Haaz MC, Riou JF, Robert J, Rivory LP. Identification of a new metabolite of CPT-11 (irinotecan): pharmacological properties and activation to SN-38. J Pharmacol Exp Ther 1998;286:578-83.
25. Rivory LP, Chatelut E, Canal P, Mathieu-Boué A, Robert J. Kinetics of the in vivo interconversion of the carboxylate and lactone forms of irinotecan (CPT-11) and its metabolite SN-38 in patients. Cancer Res 1994;54:6330-3.
26. Barilero I, Gandia D, Armand JP, Mathieu-Boue A, Re M, Gouyette A, et al. Simultaneous determination of the camptothecin analogue CPT-11 and its active metabolite SN-38 by high-performance liquid chromatography: application to plasma pharmacokinetic studies in cancer patients. J Chromatogr 1992;575:275-80.
27. Rivory LP, Robert J. Reversed-phase high-performance liquid chromatographic method for the simultaneous quantitation of the carboxylate and lactone forms of the camptothecin derivative irinotecan, CPT-11, and its metabolite SN-38 in plasma. J Chromatogr B Biomed Appl 1994;661:133-41.
28. Sumiyoshi H, Fujiwara Y, Ohune T, Yamaoka N, Tamura K, Yamakido M. High-performance liquid chromatographic determination of irinotecan (CPT-11) and its active metabolite (SN-38) in human plasma. J Chromatogr B Biomed Appl 1995;670:309-16.
29. de Bruijn P, Verweij J, Loos WJ, Nooter K, Stoter G, Sparreboom A. Determination of irinotecan (CPT-11) and its active metabolite SN-38 in human plasma by reversed-phase high-performance liquid chromatography with fluorescence detection. J Chromatogr B Biomed Sci Appl 1997;698:277-85.
30. Sparreboom A, de Bruijn P, de Jonge MJ, Loos WJ, Stoter G, Verweij J, et al. Liquid chromatographic determination of irinotecan and three major metabolites in human plasma, urine and feces. J Chromatogr B Biomed Sci Appl 1998;712:225-35.
31. Rivory LP, Findlay M, Clarke S, Bishop J. Trace analysis of SN-38 in human plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1998;714:355-9.
32. Chollet DF, Goumaz L, Renard A, Montay G, Vernillet L, Arnera V, et al. Simultaneous determination of the lactone and carboxylate forms of the camptothecin derivative CPT-11 and its metabolite SN-38 in plasma by high-performance liquid chromatography. J Chromatogr B Biomed Sci Appl 1998;718:163-75.
33. Ragot S, Marquet P, Lachatre F, Rousseau A, Lacassie E, Gaulier JM, et al. Sensitive determination of irinotecan (CPT-11) and its active metabolite SN-38 in human serum using liquid chromatography-electrpspray mass spectrometry. J Chromatogr B Biomed Sci Appl 1999;736:175-84.
34. Escoriaza J, Aldaz A, Castellanos C, Calvo E, Giraldez J. Simple and rapid determination of irinotecan and its metabolite SN-38 in plasma by high-performance liquid-chromatography: application to clinical pharmacokinetic studies. J Chromatogr B Biomed Sci Appl 2000;740:159-68.
35. Sai K, Kaniwa N, Ozawa S, Sawada J. An analytical method for irinotecan (CPT-11) and its metabolites using a high-performance liquid chromatography: parallel detection with fluorescence and mass spectrometry. Biomed Chromatogr 2002;16:209-18.
36. Schoemaker NE, Rosing H, Jansen S, Schellens JH, Beijnen JH. High-performance liquid chromatographic analysis of the anticancer drug irinotecan (CPT-11) and its active metabolite SN-38 in human plasma, Ther Drug Monit 2003;25:120-4.
37. Owens TS, Dodds H, Fricke K, Hanna SK, Crews KR. High-performance liquid chromatographic assay with fluorescence detection for the simultaneous measurement of carboxylate and lactone forms of irinotecan and three metabolites in human plasma. J Chromatogr B Biomed Sci Appl 2003;788:66-74.
38. Takahashi T, Fujiwara Y, Sumiyoshi H, Isobe T, Yamaokab N, Yamakido M. Salivary drug monitoring of irinotecan and its active metabolite in cancer patients. Cancer Chemother Pharmacol 1997;40:449-52.
39. US Food and Drug Administration. Guidance for industry. Bioanalytical method validation. May 2001. http://www.fda.gov/cder/guidance/index.htm (Accessed December 2001).
40. Validation of compendia methods. In: United States Pharmacopoeia XXXIII. Rockville, MD: The United States Pharmacopeia Convention, 2003:2439.
41. Shah VP, Midha KK, Dighe S, McGilveray IJ, Skelly JP, Yacobi A, et al. Analytical methods validation: bioavailability, bioequivalence, and pharmacokinetic studies. J Pharm Scei 1992;81:309-12.
42. Bressolle F, Bromet-Petit M, Audran M. Validation of liquid chromatographic and gas chromatographic methods. Applications in pharmacokinetics. J. Chromatogr. B 1996;686:3-10.
43. RDPP. Pk-fit computer program, Ver. 2.1, Montpellier, France: RDPP, 1999.
44. Boucaud M, Pinguet F, Poujol S, Romieu G, Cupissol D, Astre C, et al. Salivary and plasma pharmacokinetics of topotecan in patients with metastatic epithelial ovarian cancer. Eur J Cancer 2001;37:2357-64.